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Abstract
The best validated susceptibility variants for Parkinson’s disease (PD) are located in the alpha-
synuclein (SNCA) and microtubule-associated protein tau (MAPT) genes. Recently, a protective
p.N551K-R1398H-K1423K haplotype in the leucine-rich repeat kinase 2 (LRRK2) gene was
identified, with p.R1398H appearing to be the most likely functional variant. To date, the
consistency of the protective effect of LRRK2 p.R1398H across MAPT and SNCA variant
genotypes has not been assessed. To address this, we examined four SNCA variants (rs181489,
rs356219, rs11931074, rs2583988), the MAPT H1-haplotype defining variant rs1052553, and
LRRK2 p.R1398H (rs7133914) in Caucasian (N=10,322) and Asian (N=2,289) series. There was
no evidence of an interaction of LRRK2 p.R1398H with MAPT or SNCA variants (all P≥0.10);
the protective effect of p.R1398H was observed at similar magnitude across MAPT and SNCA
genotypes, and the risk effects of MAPT and SNCA variants were observed consistently for
LRRK2 p.R1398H genotypes. Our results indicate that the association of LRRK2 p.R1398H with
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PD is independent of SNCA and MAPT variants, and vice versa, in Caucasian and Asian
populations.
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Parkinson disease; LRRK2; SNCA; MAPT; interaction; genetics
1. Introduction
With an estimated prevalence of between 1% and 2% in individuals older than 65,
Parkinson’s disease (PD) is one of the most common age-related neurodegenerative
disorders (de Lau and Breteler, 2006; Postuma and Montplaisir, 2009). Long thought of as a
sporadic disease, PD now has a well-established genetic component which includes both
disease-causing mutations as well as risk-modifying susceptibility variants (Gasser et al.,
2011). Of the PD susceptibility variants that have been identified thus far, the best validated
have involved those located in the α-synuclein (SNCA) gene, which also contains several
pathogenic mutations that are linked to familial PD, and in the microtubule-associated
protein tau (MAPT) gene (Gasser et al., 2011). More specifically, associations with PD have
been identified in both Caucasian and Asian populations at the 3′ and 5′ ends of the SNCA
gene (Mizuta et al., 2006; Mueller et al., 2005; Pankratz et al., 2009; Ross et al., 2007;
Satake et al., 2009; Simón-Sánchez et al., 2009; Winkler et al., 2007), while the H1
haplotype in MAPT is associated with PD in Caucasians, but not in Asians owing to the
almost complete absence of the H2 haplotype in that group (Evans et al., 2004; Healy et al.,
2004; Skipper et al., 2004; Tobin et al., 2008; Wider et al., 2010).
Variation in the leucine-rich repeat kinase 2 (LRRK2) gene, which like SNCA harbors
disease-causing mutations of its own, has also been associated with susceptibility to PD in
both Caucasian and Asian populations. The majority of proposed LRRK2 PD risk variants
have been relatively rare (minor allele frequencies [MAFs] between 1% and 5%) and have
included p.G2385R and p.R1628P in Asian populations as well as the more recently
identified p.A419V (Asians), and p.M1646T (Caucasians) (Di Fonzo et al., 2006; Farrer et
al., 2007; Ross et al., 2008; Ross et al., 2011; Tan et al., 2010). The most common LRRK2
PD risk factor to date, identified by several groups including our own, has involved a 3-
variant (p.N551K-R1398H-K1423K) protective haplotype in both populations (Ross et al.,
2011; Tan et al., 2010). It has been shown that the p.1398H variant has reduced kinase
activity in comparison to the wild type p.R1398 (Tan et al. 2010). Given these data, the
p.R1398H (rs7133914) substitution, which occurs with a MAF of approximately 7% in
Caucasians and 10% in Asians (Heckman et al., in press; Tan et al., 2010), is the most likely
functional variant on the haplotype. The protective effect of p.R1398H appears strongest in
Asians, where consistent odds ratios of 0.75 and 0.73 have been observed in studies by Tan
et al. (2010) and Ross et al. (2011), with a similar odds ratio of 0.79 observed in a smaller
study by Chen et al. (2011). In Caucasians, the odds ratio for p.R1398H observed in the
aforementioned study by Ross et al. in a series of 6995 patients and 5595 controls was 0.89.
This is very similar to the findings of a large meta-analysis of genome-wide association
studies, where although not nominally significant, LRRK2 p.R1398H (MAF~6.7%) had a
protective odds ratio of 0.92 and 95% confidence limits ranging from 0.83 to 1.02 in regard
to susceptibility to PD (Nalls et al. 2011; Personal Communication).
In order to best determine risk of PD for a given individual and understand potential future
therapeutic implications, it is important not only to identify individual genetic risk factors
but also to understand how these risk factors interact with one another. However, sample
sizes needed to reasonably evaluate evidence of such gene-gene interactions are usually
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fairly large and can be difficult to achieve. This is due to the fact that the risk factor of
interest in an interaction study (presence of the genotype of interest for both variants) occurs
much less frequently than the genotype for the individual variants, which can result in a lack
of precision in estimated interaction effects. Collaboration between members of the Genetic
Epidemiology of Parkinson’s Disease (GEO-PD) Consortium and the resulting large number
of patients with PD and controls offers the opportunity to effectively examine how
recognized susceptibility variants for PD may or may not interact with one another. Such a
study was previously undertaken by the GEO-PD Consortium, where SNCA and MAPT
variants were examined in relation to risk of PD and found to have independent effects
(Elbaz et al., 2011). The identification of PD susceptibility variants in LRRK2 raises the
question of whether the effects of these variants may be modified by those in SNCA or
MAPT, or vice versa. The aim of this study was to evaluate the interaction of the common
LRRK2 susceptibility variant p.R1398H with SNCA and MAPT variants in relation to risk
of PD using Caucasian and Asian patient-control series obtained through the GEO-PD
Consortium.
2. Methods
2.1. Subjects
As of 2013, the GEO-PD Consortium includes 57 sites from 29 countries and six continents
who have agreed to share DNA and data for 38,686 patients with PD and 34,871 control
subjects (http://www.geopd.org/). A total of 20 sites participating in the GEO-PD
Consortium provided data to be used in the current study as part of a project initiated in
2009. The majority of the Caucasian subjects utilized in this study were also included in the
previously mentioned GEO-PD SNCA-MAPT interaction study (Elbaz et al., 2011), and the
subjects included in this study are a subset of those included in the previously referred to
investigation of LRRK2 exonic variants in relation to PD (Ross et al., 2011). To be
consistent with the association analysis in the latter study involving LRRK2 exonic variants,
carriers of LRRK2 pathogenic variants (N=64) were excluded. Subjects were not genotyped
for known pathogenic SNCA mutations and therefore this was not part of our exclusion
criteria. In total, 7,342 patients with PD and 5,269 controls from 13 different countries on 4
continents were studied, and these subjects were divided into a Caucasian series (5,991
patients with PD, 4,331 controls, 16 sites, 10 countries) and an Asian series (1,351 patients
with PD, 938 controls, 4 sites, 3 countries). Table 1 provides demographic information for
the Caucasian and Asians series, while site-specific information is displayed in
Supplementary Table 1.
Patients were diagnosed with PD using standard criteria (Bower et al., 1999; Gelb et al.,
1999; Hughes et al., 1992). Controls were individuals free of PD or a related movement
disorder at the time of examination. All subjects were unrelated within and between
diagnosis groups. The Mayo Clinic Institutional Review Board approved the study, each
individual site received local IRB approval, and all subjects provided informed consent.
2.2. Genetic analysis
Four SNCA variants (3′ end of gene: rs181489, rs356219, rs11931074; 5′ end of gene:
rs2583988) as well as the MAPT H1-haplotype defining variant rs1052553 were genotyped
due to consistently replicated associations with PD (Healy et al., 2004; Mizuta et al., 2006;
Mueller et al., 2005; Pankratz et al., 2009; Ross et al., 2007; Satake et al., 2009; Skipper et
al., 2004; Simón-Sánchez et al., 2009; Tobin et al., 2008; Wider et al., 2010; Winkler et al.,
2007). These five variants were chosen for the aforementioned GEO-PD SNCA-MAPT
interaction study (Elbaz et al., 2011). The REP1 polymorphism located in the SNCA
promoter has also been associated with PD (Krüger et al., 1999; Maraganore et al., 2006),
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however due to the fact that the 263bp allele (which has shown the strongest association
with PD) is relatively rare, we did not evaluate REP1 in the current study. The LRRK2
variant rs7133914 (p.R1398H) was also selected for inclusion due to the aforementioned
findings demonstrating that is the most likely functional variant on a 3-variant haplotype (all
3 variants in strong linkage disequilibrium with r2>0.84 in controls) that affects risk of PD in
a protective manner (Ross et al., 2011, Tan et al., 2010).
DNA was sourced from blood and was stored in a −80°C freezer. All samples were de-
identified with an anonymous code from each site and only a minimal clinical dataset. All
LRRK2 and SNCA genotyping was done using MassArray iPLEX chemistry and analyzed
using Typer 4.0 (Sequenom, San Diego, CA). MAPT rs1052553 was genotyped using an
ABI Taqman genotyping assay on an ABI 7900HT Fast Real-Time PCR system and
analyzed using SDS 2.2.2 software (Applied Biosystems, Foster City, CA, USA). All
genotyping was performed at the Mayo Clinic Florida neurogenetics laboratory
(Jacksonville, FL, USA). Primer sequences are provided in Supplementary Table 2 for all
variants except for MAPT rs1052553. Positive control DNA was run for each variant. Call
rates in each series were >95%. There was no evidence of departure from Hardy Weinberg
Equilibrium in controls for any of the sites (all P>0.05 after Bonferroni correction).
2.3 Statistical analysis
All analysis was performed separately for the Caucasian and Asian series. Associations of
individual SNCA variants, MAPT rs1052553, and LRRK2 p.R1398H with PD, and pair-
wise interactions of LRRK2 p.R1398H with SNCA and MAPT variants in relation to PD,
were evaluated using odds ratios (ORs) and 95% confidence intervals (CIs) from fixed-
effects logistic regression models adjusted for site. Interactions were evaluated on a
multiplicative scale only because it has been shown that when at least one of the interacting
factors is protective, biological interactions are expected to result in departure from
multiplicative effects (Weinberg, 1986).
We considered LRRK2 p.R1398H under a dominant model (presence vs. absence of the
minor allele) in all analyses owing to the very small number of homozygotes of the minor
allele, while SNCA variants were evaluated under an additive model (effect of each
additional minor allele), dominant model, recessive model (presence of two copies vs. zero
or one copy of the minor allele) and genotype model (general comparison across genotypes).
MAPT rs1052553 was also evaluated under additive, dominant, recessive, and genotype
models, but with effects corresponding to the major allele to be consistent with previous
reports where ORs correspond to the H1 risk allele. In Caucasians, three-gene interactions
were also examined. Sensitivity of results to model adjustment for age and gender and to the
use of random-effects models (DerSimonian and Laird, 1986) were also assessed when
evaluating interactions. Between-site heterogeneity in interaction ORs was examined using
chi-square tests based on the Q statistic, and also by estimating the I2 statistic, which
measures the proportion of variation in interaction ORs between sites due to heterogeneity
beyond chance (Higgins and Thompson, 2002).
A relatively large number of statistical tests of gene-gene interaction were performed in our
analyses (24 in the Caucasian series and 8 in the Asian series). In order to adjust for multiple
testing and control the family-wise error rate at 5%, we employed a Bonferroni correction
separately for each series, after which p-values≤0.0021 (Caucasian series) and ≤0.00625
(Asian series) were considered as statistically significant. All statistical analyses were
performed using R Statistical Software (version 2.14.0; R Foundation for Statistical
Computing, Vienna, Austria).
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3. Results
A summary of allele and genotype frequencies for SNCA variants, MAPT rs1052553, and
LRRK2 p.R1398H in our Caucasian and Asian patient-control series is provided in
Supplementary Table 3, along with country-specific frequencies. The SNCA variants
rs181489 and rs2583988 as well as MAPT rs1052553 were observed extremely rarely in
Asian patients and controls and as such were not assessed in association analysis. SNCA
variants were in relatively weak linkage disequilibrium in controls (r2 ≤ 0.32) with the
exception of rs181489 and rs356219 in the Caucasian series (r2=0.58), rs181489 and
rs2583988 in the Caucasian series (r2=0.53), and rs356219 and rs11931074 in the Asian
series (r2=0.97).
In order to best interpret the results of gene-gene interaction analysis, it is helpful to first
understand the effects of individual variants on risk of PD, and therefore single-variant
associations with PD for the SNCA, MAPT, and LRRK2 variants, which have largely been
reported before in the aforementioned GEO-PD studies (Elbaz et al., 2011, Ross et al.,
2011), are displayed in Supplementary Table 4. As has been previously shown, all variants
were significantly associated with PD.
Evaluations of pair-wise interactions of LRRK2 p.R1398H with SNCA variants and MAPT
rs1052553 in relation to PD for the Caucasian series are shown in Table 2. To simplify our
presentation of interaction results, we have focused on additive and genotype models for
SNCA and MAPT variants in Table 2 since all of these variants had the strongest association
with PD under an additive model except SNCA rs11931074 (which was also strongly
associated with PD under an additive model), and because genotype models allow for the
most general test of interaction. Gene-gene interactions under dominant and recessive
models for SNCA and MAPT variants are shown in Supplementary Tables 5 and 6. In site-
adjusted analyses, no interactions of LRRK2 p.R1398H with SNCA and MAPT variants
approached significance after multiple testing adjustment under any statistical model (all
interaction P≥0.10); the protective effect of p.R1398H on risk of PD observed in similar
magnitude for different genotypes of SNCA and MAPT variants, while the risk effects of
SNCA and MAPT variants were seen similarly for subjects with and without a copy of the
minor allele for p.R1398H. All interaction ORs were close to 1.0 in magnitude indicating
lack of any interaction with LRRK2 p.R1398H, the only exceptions involving rare
genotypes for MAPT rs1052553 under a dominant model (Supplementary Table 5) and
SNCA rs11931074 under a recessive model (Supplementary Table 6) which are best
interpreted with caution owing to the non-significant interactions and very low genotype
frequencies. The lack of interaction of LRRK2 p.R1398H with MAPT and SNCA variants
was also observed when adjusting for age and gender (Supplementary Table 7) in those
subjects with that information available (98%) and also when utilizing a random effects
model (Supplementary Table 8). Results of country-specific interaction analysis are shown
in Supplementary Table 9; between-site heterogeneity regarding interactions with LRRK2
p.R1398H was low for SNCA rs356219, rs11931074, and rs2583988 (I2=0%, P≥0.45) and
moderate for SNCA rs181489 and MAPT rs1052553 (I2=25% to 36%, P≥0.075)
(Supplementary Table 8).
More detailed analysis combining genotypes across all three genes for SNCA variants,
MAPT rs1052553, and LRRK2 p.R1398H in the Caucasian series is displayed in
Supplementary Table 10 and Figure 1, where rare homozygotes were collapsed with
heterozygotes for each variant in order to avoid extremely rare three-variant genotype
combinations. There was no evidence of any interaction in these three-gene analyses (all
P≥0.63).
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Interactions of LRRK2 p.R1398H with SNCA variants rs356219 and rs11931074 in the
Asian series are examined in Table 3 in analysis adjusted for site. Individual effects of
LRRK2 p.R1398H and SNCA variants on risk of PD were observed consistently across
variants in the other gene, with no statistically significant evidence of gene-gene interaction
(all interaction P≥0.14). All interaction ORs were between 1.17 and 1.39, indicating a slight
but non-significant reduction of the protective effect of LRRK2 p.R1398H on risk of PD
when the risk allele for SNCA variants was present, and a similar small and non-significant
enhancement of the SNCA risk effects given the protective genotype for p.R1398H (Figure
2). Results were similar when adjusting for age and gender (Supplementary Table 7) in the
subgroup of Asian individuals for whom that information was available (71%) and also
under a random effects model (Supplementary Table 8). Interactions between LRRK2
p.R1398H and SNCA variants under additive and recessive models are shown in
Supplementary Table 11 separately for each Asian country; between-site heterogeneity in
interactions with LRRK2 p.R1398H was moderate for both SNCA rs356219 and
rs11931074 in the Asian series (I2=46% to 55%, P≥0.084, Supplementary Table 8).
4. Discussion
Recently, a 3-variant (p.N551K-R1398H-K1423K) haplotype in the LRRK2 gene was
shown to affect susceptibility to PD in a protective manner in both Caucasian and Asian
populations (Ross et al., 2011; Tan et al., 2010). The p.R1398H substitution appears to be
the most likely functional variant as it is located in the conserved Roc domain and there is
supporting evidence of reduced kinase activity (Tan et al., 2010). While a number of
previous investigations have examined interactions between the well-validated PD
susceptibility variants located in the SNCA and MAPT genes (Biernacka et al., 2011; Elbaz
et al., 2011; Goris et al., 2007; Mamah et al., 2005; McCulloch et al., 2008; Simón-Sánchez
et al., 2009; Trotta et al., 2012; Wider et al., 2011), no report to date has examined
interactions of LRRK2 p.R1398H with SNCA and MAPT variants. The results of our large
case-control study involving both Caucasian and Asian individuals indicate that the
protective effect of LRRK2 p.R1398H is observed consistently for different SNCA and
MAPT genotypes, while similarly, the SNCA and MAPT risk effects are observed for
individuals with and without the protective p.R1398H allele.
Despite the relatively large number of interactions and statistical models considered, the
independent effects on PD risk for LRRK2 p.R1398H, MAPT rs1052553, and SNCA
variants were observed with a very high level of consistency in our study. This was most
apparent in the large Caucasian series, where all interaction odds ratios were between 0.80
and 1.13, with the exception of the two aforementioned instances involving rare genotypes
for MAPT rs1052553 and SNCA rs11931074. Additionally, between-site heterogeneity in
interaction effects was low to moderate in Caucasians. Although the protective effect of
LRRK2 p.R1398H on risk of PD was observed consistently across SNCA variant genotypes
in Asians, perhaps the least convincing evidence of lack of gene-gene interaction was
observed in this series. Though not approaching significance even before adjustment for
multiple testing, the magnitude of this observed protective effect was slightly smaller when
the risk genotype for SNCA variants was present, while conversely the observed risk effects
of SNCA variants were marginally stronger in individuals with the protective p.R1398H
genotypes. Additionally, heterogeneity in interaction effects between sites was highest in the
Asian series. However, it is important to highlight that it would be very unusual to observe a
complete lack of gene-gene interaction (i.e. interaction odds ratio equal to 1) in all scenarios
simply due to natural sampling variability, particularly given the number of possible
interactions that were examined. Nonetheless, given the smaller size of our Asian series in
comparison to the Caucasian series, it will be important to validate our findings in larger
series of Asian individuals.
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Recent studies have supported our earlier work indicating that the effects of SNCA and
MAPT variants on PD risk are independent of one another (Biernacka et al., 2011; Trotta et
al., 2012; Wider et al., 2011). Though our current study is the first to date to examine the
potential interaction of the protective LRRK2 p.R1398H substitution with MAPT and
SNCA variants in regard to risk of PD, previous studies have evaluated interactions with, or
combined effects of, LRRK2 variants and those in SNCA and MAPT. In their analysis of
1098 patients with PD and 1098 matched controls from the United States (a subset of which
were also used in the current study), Biernacka et al. (2011) found no statistically significant
evidence of gene-gene interaction when considering 8 intronic LRRK2 variants, 10 SNCA
variants (eight intronic, one 3′ downstream, and 5′ Rep1), and 8 MAPT variants (six
intronic, one 3′ UTR, and H1/H2). Wang et al. (2012) concluded that other genes, including
MAPT and SNCA, modified LRRK2-related risk for PD in a Chinese cohort of 2,013
sporadic PD patients and 1,971 controls. This was based on findings that in comparison to
individuals harboring only the LRRK2 p.G2385R or p.R1628P risk variants, the risk of PD
is increased in individuals with these and other PD risk variants. However, it is unclear
whether this represents independent or interactive effects, and the sample sizes of the
combined risk-variant groups examined were quite small. The results of these studies are
consistent with those of our own, with the effect of LRRK2 variants on PD susceptibility
appearing to be independent of SNCA and MAPT risk factors for PD.
While the strengths of our study, including the large sample size and inclusion of subjects
from a variety of different populations, are important to highlight, several limitations should
also be acknowledged. A key question is whether the lack of interaction of LRRK2
p.R1398H with SNCA and MAPT variants is a consequence of sample size or the
frequencies of the examined variants. In order to assess the possibility of a false-negative
association, it is most helpful to examine 95% confidence limits for observed interaction
odds ratio estimates (Goodman and Berlin, 1994). These confidence limits were generally
relatively tight in the larger Caucasian series indicating a lack of a biologically significant
interaction in this population, but were wider in the Asian series, further highlighting the
need for validation of our findings in that series. Additionally, as is generally the case for
large-scale collaborative studies attempting to address a focused research question that
involves a small number of genetic variants, without available genome-wide population
control markers, population stratification could potentially have had an impact on our
results. However, this potential limitation is lessened by the fact that our logistic regression
models were adjusted by site, which makes any possible population stratification a site-
specific issue. Other limitations of our study include the different diagnostic criteria across
the different sites and the lack of a standardized inclusion/exclusion criteria for patients with
PD and controls.
In conclusion, our study provides evidence that the effect of LRRK2 p.R1398H on risk of
PD is independent of the MAPT H1-haplotype defining variant rs1052553 and SNCA
variants, and vice versa. This lack of gene-gene interaction was apparent in both our large
Caucasian patient-control series and our smaller Asian series. Evaluation of interactions
involving individuals of other ethnic backgrounds, other rarer LRRK2 susceptibility
variants, and PD susceptibility variants at other loci (Lill et al., 2012) is needed in order to
move toward a fuller understanding of the genetic architecture of PD susceptibility.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
A) Individual and combined effects of SNCA rs181489, MAPT rs1052553, and LRRK2
p.R1398H on risk of PD in the Caucasian series. For SNCA rs181489, the risk genotype was
CT or TT (i.e. presence of the minor allele); B) Individual and combined effects of SNCA
rs356129, MAPT rs1052553, and LRRK2 p.R1398H on risk of PD in the Caucasian series.
For SNCA rs356129, the risk genotype was AG or GG (i.e. presence of the minor allele); C)
Individual and combined effects of SNCA rs11931074, MAPT rs1052553, and LRRK2
p.R1398H on risk of PD in the Caucasian series. For SNCA rs11931074, the risk genotype
was GT or TT (i.e. presence of the minor allele); D) Individual and combined effects of
SNCA rs2583988, MAPT rs1052553, and LRRK2 p.R1398H on risk of PD in the Caucasian
series. For SNCA rs2583988, the risk genotype was CT or TT (i.e. presence of the minor
allele). Figures 1A–1D) For MAPT rs1052553, the risk genotype was AA (i.e. presence of
two copies of the major allele); for LRRK2 p.R1398H, the protective genotype was GA or
AA (i.e. presence of the minor allele); NA indicates that a given SNP was not involved in
the particular portion of the analysis.
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Figure 2.
A) Individual and combined effects of SNCA rs356219, SNCA rs11931074, and LRRK2
p.R1398H on risk of PD in the Asian series. SNCA rs356219 and rs11931074 were
considered under a recessive model (i.e. presence vs. absence of two copies of the minor
allele). For SNCA rs356219, the risk genotype was GG. For SNCA rs11931074, the risk
genotype was TT; B) Individual and combined effects of SNCA rs356219, SNCA
rs11931074, and LRRK2 p.R1398H on risk of PD in the Asian series. SNCA rs356219 and
rs11931074 were considered under a dominant model (i.e. presence vs. absence of the minor
allele). For SNCA rs356219, the risk genotype was AG or GG. For SNCA rs11931074, the
risk genotype was GT or TT. Figures 2A–2B) For LRRK2 p.R1398H, the protective
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genotype was GA or AA (i.e. presence of the minor allele); NA indicates that a given SNP
was not involved in the particular portion of the analysis.
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Table 1
Patient characteristics for the Caucasian and Asian series
Variable Patients with PD Controls
Caucasian series N=5,991 N=4,331
 Age 69 ± 11 (18 – 106) 65 ± 15 (21 – 107)
 Gender
  Male 3453 (58%) 2045 (47%)
  Female 2538 (42%) 2286 (53%)
 Age at onset 59 ± 12 (18 – 96) NA
Asian series N=1,351 N=938
 Age 61 ± 12 (20 – 91) 60 ± 11 (23 – 89)
 Gender
  Male 672 (50%) 322 (34%)
  Female 679 (50%) 616 (66%)
 Age at onset 54 ± 12 (20 – 89) NA
The sample mean ± SD (minimum – maximum) is given for age and age at onset. Information was unavailable regarding age in the Caucasian
series (147 patients with PD, 21 controls) and Asian series (371 patients with PD, 298 controls). Information was unavailable regarding age at onset
in the Caucasian series (723 patients) and Asian series (8 patients). NA=not applicable. SD=standard deviation.
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f t
he
 m
in
or
 a
lle
le
 fo
r L
RR
K
2 
p.
R1
39
8H
 o
n 
PD
 co
rre
sp
on
di
ng
 to
 p
re
se
nc
e o
f t
w
o 
ris
k 
al
le
le
s f
or
 S
NC
A
v
ar
ia
nt
s, 
or
 a
lte
rn
at
iv
el
y 
as
 th
e 
as
 th
e 
m
ul
tip
lic
at
iv
e 
in
cr
ea
se
 in
 th
e 
ef
fe
ct
 o
f p
re
se
nc
e 
of
 tw
o 
ris
k 
al
le
le
s f
or
 S
NC
A 
v
ar
ia
nt
s o
n 
PD
 c
or
re
sp
on
di
ng
 to
 p
re
se
nc
e 
of
 th
e 
m
in
or
 a
lle
le
 fo
r L
RR
K
2 
p.
R1
39
8H
.
4 T
es
ts
 o
f i
nt
er
ac
tio
n 
un
de
r a
 g
en
ot
yp
e 
m
od
el
 d
o 
no
t p
ro
du
ce
 a
 si
ng
le
 in
te
ra
ct
io
n 
O
R,
 a
nd
 th
er
ef
or
e 
on
ly
 a
 p
-v
al
ue
 is
 g
iv
en
. O
R=
od
ds
 ra
tio
. C
I=
co
nf
id
en
ce
 in
te
rv
al
.
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